MRKR Stock Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Marker Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.34 |
52 Week High | US$9.68 |
52 Week Low | US$0.67 |
Beta | 1.49 |
1 Month Change | 14.68% |
3 Month Change | -24.61% |
1 Year Change | 410.00% |
3 Year Change | -80.65% |
5 Year Change | -93.22% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Marker shares rise as it completes construction of its cGMP manufacturing facility
Jan 13FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy
Jan 05Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29Marker Therapeutics EPS misses by $0.02
Nov 09Shareholder Returns
MRKR | US Biotechs | US Market | |
---|---|---|---|
7D | -3.7% | 0.9% | 0.4% |
1Y | 410.0% | 10.3% | 28.8% |
Return vs Industry: MRKR exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: MRKR exceeded the US Market which returned 29.5% over the past year.
Price Volatility
MRKR volatility | |
---|---|
MRKR Average Weekly Movement | 13.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRKR's share price has been volatile over the past 3 months.
Volatility Over Time: MRKR's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 67 | Juan Vera | https://www.markertherapeutics.com |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications.
Marker Therapeutics, Inc. Fundamentals Summary
MRKR fundamental statistics | |
---|---|
Market cap | US$38.53m |
Earnings (TTM) | -US$14.05m |
Revenue (TTM) | US$3.31m |
11.6x
P/S Ratio-2.7x
P/E RatioIs MRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRKR income statement (TTM) | |
---|---|
Revenue | US$3.31m |
Cost of Revenue | US$10.42m |
Gross Profit | -US$7.11m |
Other Expenses | US$6.94m |
Earnings | -US$14.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.58 |
Gross Margin | -214.60% |
Net Profit Margin | -424.20% |
Debt/Equity Ratio | 0% |
How did MRKR perform over the long term?
See historical performance and comparison